Stocks › ARWR
ARROWHEAD PHARMACEUTICALS, INC.
ARWR·Nasdaq·
United States·USD
United States·USD$61.54
-0.81 (-1.30%)
Close · Oct 6, 2026 · Close Prices from Tiingo.com
ARWR
ARROWHEAD PHARMACEUTICALS, INC. · Nasdaq
Nasdaq 100S&P 500
Filings
Default90D1Y5YALL
ARWRS&P 500 (rebased)
Congress BuyCongress SellInsider BuyInsider SellForm 1448-K ResultsLobbying
Loading price history…
Daily closes, adjusted for splits and dividends · Close Prices from Tiingo.comHover a marker, every one is a filing · move across the line for the crosshair
Congressional Trades
Recent trades of ARWR by members of U.S. Congress · 1 on record
| Politician | Stock | Type | Filed | Traded | |
|---|---|---|---|---|---|
 Daniel S. GoldmanHouse · D · NY |
ARWRARROWHEAD PHARMACEUTICALS, INC. · Stock |
Sale $1,001 - $15,000 |
Feb 24, 2023 | Jan 31, 2023 | Filing ↗ |
Whale Activity
Position changes in ARWR reported for 2026-09-30 by 1 tracked institutional filer
- Increased0
- New0
- Held0
- Decreased0
- Closed0
- No prior filing1
| Filer | Shares | Value | Change |
|---|---|---|---|
| Acasta Partners UK LLP | 1.5M | $1.5M | — |
KeyVex tracks a curated set of large 13F filers plus the largest positions in recent filings, so this is a sample of institutional activity, not the whole market.
Insider Trading
Net shares bought (+) or sold (−) on the open market by ARWR insiders, by quarter · Form 4
Recent Insider Transactions
744 transactions on record · newest first
| Insider | Type | Shares | Price | Value | Date | |
|---|---|---|---|---|---|---|
| PERRY MICHAEL SDirector · Director | Sale | −11.6K | $87.30 | $1.0M | Aug 18, 2026 | Form 4 ↗ |
| OLUKOTUN ADEOYE YDirector · Director | Sale | −2,000 | $86.96 | $174K | Aug 18, 2026 | Form 4 ↗ |
| Cohen Matthew GregoryDirector | Grant / award | +11.9K | $0.00 | $0 | Jun 15, 2026 | Form 4 ↗ |
| Lu HongboDirector | Sale | −2,970 | $76.88 | $228K | May 12, 2026 | Form 4 ↗ |
| Hamilton James CChief Medical Officer | Sale | −10.0K | $75.00 | $750K | Apr 23, 2026 | Form 4 ↗ |
| Apel Daniel JosephChief Financial Officer | Sale | −8,730 | $71.92 | $628K | Apr 22, 2026 | Form 4 ↗ |
| Apel Daniel JosephChief Financial Officer | Sale | −1,157 | $70.45 | $82K | Apr 22, 2026 | Form 4 ↗ |
| Apel Daniel JosephChief Financial Officer | Sale | −3,208 | $70.11 | $225K | Apr 22, 2026 | Form 4 ↗ |
| Hamilton James CChief Medical Officer | Sale | −10.0K | $64.19 | $642K | Mar 5, 2026 | Form 4 ↗ |
| Apel Daniel JosephChief Financial Officer | Grant / award | +75.0K | $0.00 | $0 | Jan 6, 2026 | Form 4 ↗ |
| Hamilton James CChief Medical Officer | Grant / award | +75.0K | $0.00 | $0 | Jan 6, 2026 | Form 4 ↗ |
| O'Brien PatrickCOO | Grant / award | +75.0K | $0.00 | $0 | Jan 6, 2026 | Form 4 ↗ |
| O'Brien PatrickCOO | Gift | −440 | $0.00 | $0 | Jan 6, 2026 | Form 4 ↗ |
| O'Brien PatrickCOO | Gift | −440 | $0.00 | $0 | Jan 6, 2026 | Form 4 ↗ |
| O'Brien PatrickCOO | Gift | −540 | $0.00 | $0 | Jan 6, 2026 | Form 4 ↗ |
| O'Brien PatrickCOO | Gift | −540 | $0.00 | $0 | Jan 6, 2026 | Form 4 ↗ |
| O'Brien PatrickCOO | Gift | −540 | $0.00 | $0 | Jan 6, 2026 | Form 4 ↗ |
| Hamilton James CChief Medical Officer | Sale | −309 | $68.00 | $21K | Jan 5, 2026 | Form 4 ↗ |
| Hamilton James CChief Medical Officer | Sale | −437 | $65.97 | $29K | Jan 5, 2026 | Form 4 ↗ |
| Hamilton James CChief Medical Officer | Sale | −1,200 | $64.49 | $77K | Jan 5, 2026 | Form 4 ↗ |
Fund Holders
Mutual funds and ETFs holding ARWR · SEC Form N-PORT
| Fund | Shares | Value | % of fund | As of |
|---|---|---|---|---|
| iShares Core S&P Mid-Cap ETF iShares Trust | 4.8M | $392.9M | 0.32% | Jun 30, 2026 |
| VANGUARD TOTAL STOCK MARKET INDEX FUND VANGUARD INDEX FUNDS | 4.2M | $346.1M | 0.02% | Jun 30, 2026 |
| VANGUARD SMALL-CAP INDEX FUND VANGUARD INDEX FUNDS | 3.1M | $250.1M | 0.13% | Jun 30, 2026 |
| iShares Russell 2000 ETF iSHARES TRUST | 3.3M | $207.2M | 0.29% | Mar 31, 2026 |
| Fidelity Growth Company Fund Fidelity Mt. Vernon Street Trust | 2.4M | $184.1M | 0.19% | May 31, 2026 |
| Invesco S&P MidCap Momentum ETF Invesco Exchange-Traded Fund Trust | 1.7M | $147.0M | 2.05% | Jul 31, 2026 |
| VANGUARD SMALL-CAP GROWTH INDEX FUND VANGUARD INDEX FUNDS | 1.8M | $144.2M | 0.31% | Jun 30, 2026 |
| VANGUARD EXTENDED MARKET INDEX FUND VANGUARD INDEX FUNDS | 1.6M | $131.6M | 0.13% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P(R) Biotech ETF SPDR SERIES TRUST | 1.4M | $114.7M | 1.07% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund Fidelity Salem Street Trust | 1.3M | $98.3M | 0.30% | Apr 30, 2026 |
Mutual funds and ETFs whose N-PORT filings list ARWR's shares (CUSIP 04280A100), each fund at its latest report since Mar 7, 2026, largest positions first. Bonds, options and short positions are left out.
Activist & Passive Stakes
Schedule 13D / 13G beneficial-ownership filings
- Behzad AghazadehSCHEDULE 13G/A · passive (13G) · 13.8M shares9.6%
Aug 14, 2026 · ↗ - Avoro Capital Advisors LLCSCHEDULE 13G/A · passive (13G) · 13.8M shares9.6%
Aug 14, 2026 · ↗ - Vanguard Portfolio ManagementSCHEDULE 13G/A · passive (13G) · 6.4M shares4.5%
Jul 31, 2026 · ↗ - BlackRock, Inc.SCHEDULE 13G/A · passive (13G) · 14.2M shares10.1%
Jul 27, 2026 · ↗ - Abigail P. JohnsonSCHEDULE 13G · passive (13G) · 7.3M shares5.2%
May 6, 2026 · ↗ - FMR LLCSCHEDULE 13G · passive (13G) · 7.3M shares5.2%
May 6, 2026 · ↗
Corporate Lobbying
Estimated quarterly lobbying spending reported under the LDA, filings naming ARROWHEAD PHARMACEUTICALS, INC. as client
No lobbying filings found naming ARROWHEAD PHARMACEUTICALS, INC. as the client.
Government Contracts
Federal awards to ARROWHEAD PHARMACEUTICALS, INC. · USAspending
No federal contract awards found for ARROWHEAD PHARMACEUTICALS, INC..
U.S. Patents
Recent USPTO applications naming ARROWHEAD PHARMACEUTICALS, INC.
No USPTO patent applications found for ARROWHEAD PHARMACEUTICALS, INC..
Annual Financials
From ARWR's 10-K filings · XBRL
No annual XBRL figures on record for ARWR. KeyVex's fundamentals cover about 130 large companies so far.
Stock Splits
Every split and reverse split in the price history
- 1-for-10Reverse splitNov 17, 2011
- 1-for-65Reverse splitJan 15, 2004
Split dates and ratios from the price history · Close Prices from Tiingo.com
About ARROWHEAD PHARMACEUTICALS, INC.
From SEC EDGAR company records
Industry (SIC 2834)Pharmaceutical Preparations
SectorHealthcare
HeadquartersPASADENA, CA
IncorporatedDE
SEC CIK0000879407 ↗
Former namesARROWHEAD RESEARCH CORP, INTERACTIVE GROUP INC, INTERACTIVE INC